ENZA-p 子研究:中期 PSMA-PET 总肿瘤体积对总生存的预后价值
ENZA-p 是一项随机 2 期试验,比较恩扎卢胺单药与联合 [177Lu]Lu-PSMA-617 治疗 mCRPC。本子研究纳入 152 例有 3 个月 PSMA-PET 数据的患者,评估 3 个月 PSMA-TTV 变化及残留体积对 OS 的预后价值。结果显示 3 个月 PSMA-TTV 升高或残留体积高于中位数均与更短 OS 相关,且独立于治疗臂和 PSA 反应。
要点
- 3 个月 PSMA-TTV 任何升高 vs 下降与更短 OS 相关(HR 2.52)。
- 3 个月残留 PSMA-TTV 高于中位数 103 ml 与更短 OS 相关(HR 3.76)。
- 该预后关联独立于治疗臂和 PSA 反应。
核心结论
- 3 个月 PSMA-TTV 在 ENZA-p 中对 OS 具有预后价值,独立于研究治疗和 PSA 反应,值得进一步前瞻性验证中期 PSMA-PET 反应标准。
研究设计与样本
- ENZA-p 为随机 2 期试验,mCRPC 且具有恩扎卢胺早期治疗失败风险因素的患者按 1:1 随机接受恩扎卢胺或恩扎卢胺联合 [177Lu]Lu-PSMA-617。
- 本子研究纳入 152/162(94%)例随机参与者,具有 3 个月 PSMA-PET 数据,基线及 3 个月行 [68Ga]Ga-PSMA-11-PET/CT 并量化 PSMA-TTV。
主要发现
- 中位 OS 为 27 个月(95%CI 23-30)。
- 基线中位 PSMA-TTV 230 ml(IQR 75-635),3 个月中位 PSMA-TTV 103 ml(IQR 24-457)。
- PSMA-TTV 自基线中位变化为 -34%(IQR -76% 至 16%),50/152(33%)例参与者 PSMA-TTV 升高。
- 3 个月 PSMA-TTV 任何升高 vs 下降与更短 OS 相关(HR 2.52,95%CI 1.65-3.85),2 年生存率分别为 30%(95%CI 17-43) vs 67%(95%CI 56-75)(log-rank p < 0.0001)。
- 3 个月残留 PSMA-TTV 高于 vs 低于中位数(103 ml)与更短 OS 相关(HR 3.76,95%CI 2.39-5.92),2 年生存率分别为 34%(95%CI 23-45) vs 76%(95%CI 64-84)(log-rank p < 0.0001)。
临床怎么用
- 中期 PSMA-PET 总肿瘤体积变化及残留体积可用于 mCRPC 患者 OS 风险分层,辅助临床决策。
局限性
- 本研究为 ENZA-p 子研究,样本量有限(152 例),中期 PSMA-PET 反应标准仍需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Interim [68Ga]Ga-prostate-specific membrane-antigen positron emission tomography/computed tomography (PSMA-PET/CT) has prognostic potential for overall survival (OS) in metastatic castrate-resistant prostate cancer (mCRPC), although evidence is limited. This ENZA-p sub-study evaluated 3-mo PSMA-total-tumor-volume (PSMA-TTV) as a prognostic biomarker for OS with enzalutamide ± [177Lu]Lu-PSMA-617. METHODS: ENZA-p is a randomized, phase 2 trial. Participants with mCRPC and risk factors for early treatment failure with enzalutamide were randomized (1:1) to enzalutamide or enzalutamide + [177Lu]Lu-PSMA-617. Participants underwent baseline and 3-mo [68Ga]Ga-PSMA-11-PET/CT, quantified to derive PSMA-TTV. We evaluated the prognostic value of PSMA-TTV change, and residual PSMA-TTV at 3-mo for OS (NCT04419402). KEY FINDINGS AND LIMITATIONS: This sub-study included 152/162 (94%) randomized participants with a 3-mo PSMA-PET. Median OS was 27 mo (95% confidence interval [CI] 23-30). Baseline median PSMA-TTV 230 ml (interquartile range [IQR] 75-635) and 3-mo PSMA-TTV 103 ml (IQR 24-457). The median change in PSMA-TTV from baseline was -34% (IQR -76% to 16%) with 50/152 (33%) participants with increase in PSMA-TTV. Any increase versus decrease in PSMA-TTV at 3-mo was associated with shorter OS (HR 2.52, 95% CI 1.65-3.85) and decreased 2-yr survival 30% (95% CI 17-43) versus 67% (95% CI 56-75) (log-rank p < 0.0001). Residual 3-mo PSMA-TTV higher versus lower than the median (103 ml) was associated with shorter OS (HR 3.76, 95% CI 2.39-5.92) and lower 2-yr survival 34% (95% CI 23-45) versus 76% (95% CI 64-84) (log-rank p < 0.0001). This association was independent of treatment arm and prostate-specific antigen (PSA) response. CONCLUSIONS AND CLINICAL IMPLICATIONS: PSMA-TTV at 3 mos was prognostic for OS independent of study treatment and PSA response in ENZA-p, warranting further prospective validation of interim PSMA-PET response criteria.
引用
- Emmett L, Papa N, Sartor O, et al. Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901). Eur Urol. 2026. PMID: 41956861. doi:10.1016/j.eururo.2026.03.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。